Chatterjee Dattatreyo, Roy Somnath, Hazra Avijit, Dasgupta Partha, Ganguly Subir, Das Anup Kumar
Department of Pharmacology, R. G. Kar Medical College and Hospital, Kolkata, West Bengal, India.
Department of Radiotherapy, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India.
Indian J Pharmacol. 2014 Mar-Apr;46(2):222-4. doi: 10.4103/0253-7613.129325.
Toxicity of cancer chemotherapy may be affected by nutritional status of patients which is reflected in the body mass index (BMI). We sought to assess whether the adverse drug reaction (ADR) profile of platinum-based chemotherapy varies with BMI status.
Adult patients of either sex, suffering from a solid tumor (lung, head and neck, ovary, gall bladder, stomach, colon) and started on platinum-based chemotherapy as initial treatment were included. BMI at chemotherapy commencement was obtained from medical records. Events were recorded and graded as per Eastern Co-operative Oncology Group Common Toxicity Criteria-patients' complaints; clinically evident signs and laboratory reports were considered. Frequencies of individual adverse events were compared between low BMI (<18.5 kg/m(2)) and satisfactory BMI groups. Similar comparisons were done for events with grades 2 or 3 severities.
A total of 50 patients were observed over a 3-month period of whom 17 (34%) belonged to the low BMI group. Nausea, vomiting, diarrhea, stomatitis, anemia, alopecia, tinnitus and paresthesia were the commonly observed ADRs. The frequencies of anemia (P = 0.152) and vomiting (P = 0.140) and severity of grades of nausea (P = 0.066), anemia (P = 0.120) and paresthesia (P = 0.128) showed a higher trend in the low BMI group though differences were not statistically significant. The frequencies of tinnitus (P = 0.021) and paresthesia overall (P = 0.036) were significantly higher in the low BMI group.
ADR profile of primary platinum-based chemotherapy appears to be partly influenced by BMI. This suggests the importance of maintaining adequate nutrition in patients and the need for greater vigilance in those with low BMI.
癌症化疗的毒性可能受患者营养状况的影响，而营养状况可通过体重指数（BMI）反映出来。我们试图评估铂类化疗的药物不良反应（ADR）情况是否随BMI状态而变化。
纳入成年男女患者，他们患有实体瘤（肺癌、头颈癌、卵巢癌、胆囊癌、胃癌、结肠癌）并开始接受铂类化疗作为初始治疗。化疗开始时的BMI从病历中获取。根据东部肿瘤协作组通用毒性标准记录事件并分级——考虑患者的主诉、临床明显体征和实验室报告。比较低BMI（<18.5 kg/m²）组和BMI正常组个体不良事件的发生率。对2级或3级严重程度的事件进行类似比较。
在3个月期间共观察了50例患者，其中17例（34%）属于低BMI组。恶心、呕吐、腹泻、口腔炎、贫血、脱发、耳鸣和感觉异常是常见的ADR。贫血（P = 0.152）和呕吐（P = 0.140）的发生率以及恶心（P = 0.066）、贫血（P = 0.120）和感觉异常（P = 0.128）的分级严重程度在低BMI组有更高的趋势，尽管差异无统计学意义。低BMI组耳鸣（P = 0.021）和总体感觉异常（P = 0.036）的发生率显著更高。
一线铂类化疗的ADR情况似乎部分受BMI影响。这表明在患者中维持充足营养的重要性以及对低BMI患者需要更加警惕。
